Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CBMG

Cellular Biomedicine Group (CBMG) Stock Price, News & Analysis

Cellular Biomedicine Group logo

About Cellular Biomedicine Group Stock (NASDAQ:CBMG)

Key Stats

Today's Range
N/A
50-Day Range
$17.67
$19.75
52-Week Range
N/A
Volume
8,375 shs
Average Volume
129,776 shs
Market Capitalization
$384.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Receive CBMG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellular Biomedicine Group and its competitors with MarketBeat's FREE daily newsletter.

CBMG Stock News Headlines

Consumer Cellular Announces New Barbie™ Flip Phone
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Intra-Cellular price target raised to $119 from $113 at Canaccord
See More Headlines

CBMG Stock Analysis - Frequently Asked Questions

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) issued its quarterly earnings results on Monday, November, 9th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.25. The biotechnology company had revenue of $0.03 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellular Biomedicine Group investors own include CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), Aduro Biotech (ADRO), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Bristol-Myers Squibb (BMY) and Intellia Therapeutics (NTLA).

Company Calendar

Last Earnings
11/09/2020
Today
11/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CBMG
Fax
N/A
Employees
217
Year Founded
N/A

Profitability

Net Income
$-49,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$340,000.00
Book Value
$2.89 per share

Miscellaneous

Free Float
N/A
Market Cap
$384.69 million
Optionable
Optionable
Beta
1.35
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CBMG) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners